NCT06260514View on ClinicalTrials.gov

Study of APR-1051 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

79

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

APR-1051

WEE1 Inhibitor

Trial Locations (3)

75039

RECRUITING

NEXT Oncology -Dallas, Irving

77030

RECRUITING

MD Anderson Cancer Center (MDACC), Houston

78229

RECRUITING

NEXT Oncology -San Antonio, San Antonio

Sponsors

Lead Sponsor

Aprea Therapeutics

All Listed Sponsors

lead

Aprea Therapeutics

INDUSTRY